Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eli Lilly | NYSE | Healthcare | Pharmaceuticals | $831.77B | 113.6x | 8.64 | $924.51 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.3% Upside | Upgrade to Pro+ | |
Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | $563.25B | 42.2x | 1.3 | $127.37 | -5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.6% Upside | Upgrade to Pro+ | |
J&J | NYSE | Healthcare | Pharmaceuticals | $395.61B | 10.5x | 0.11 | $164.38 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.7% Upside | Upgrade to Pro+ | |
AbbVie | NYSE | Healthcare | Pharmaceuticals | $340.30B | 64.2x | -1.68 | $192.66 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.6% Upside | Upgrade to Pro+ | |
Merck&Co | NYSE | Healthcare | Pharmaceuticals | $297.16B | 21.6x | 0.06 | $117.01 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.5% Upside | Upgrade to Pro+ | |
Roche Holding Participation | OTC Markets | Healthcare | Pharmaceuticals | $269.85B | 21.7x | -6.19 | $312.91 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | $269.85B | 21.7x | -6.19 | $39.56 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.5% Upside | Upgrade to Pro+ | |
AstraZeneca ADR | NASDAQ | Healthcare | Pharmaceuticals | $242.55B | 37.7x | 8.83 | $78.36 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.2% Upside | Upgrade to Pro+ | |
AstraZeneca PLC | OTC Markets | Healthcare | Pharmaceuticals | $242.55B | 37.7x | 8.83 | $157.73 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Novartis ADR | NYSE | Healthcare | Pharmaceuticals | $235.06B | 14.7x | 0.2 | $116.28 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.3% Upside | Upgrade to Pro+ | |
Novartis | OTC Markets | Healthcare | Pharmaceuticals | $235.06B | 14.7x | 0.2 | $113.99 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -27.2% Downside | Upgrade to Pro+ | |
Amgen | NASDAQ | Healthcare | Pharmaceuticals | $181.18B | 57.7x | -0.94 | $337.04 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.6% Downside | Upgrade to Pro+ | |
Pfizer | NYSE | Healthcare | Pharmaceuticals | $165.81B | -63.7x | 0.57 | $29.28 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.2% Upside | Upgrade to Pro+ | |
Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | $144.27B | 14.3x | -0.6 | $57.62 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.9% Upside | Upgrade to Pro+ | |
Gilead | NASDAQ | Healthcare | Pharmaceuticals | $103.70B | 98.4x | -1.21 | $83.30 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.3% Downside | Upgrade to Pro+ | |
Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | $99.38B | -15.3x | 0.08 | $49.11 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.7% Upside | Upgrade to Pro+ | |
CSL | OTC Markets | Healthcare | Pharmaceuticals | $97.01B | 36.6x | 1.82 | $99.35 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.2% Upside | Upgrade to Pro+ | |
Zoetis Inc | NYSE | Healthcare | Pharmaceuticals | $86.81B | 37.5x | 4.98 | $191.67 | -0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 11.7% Upside | Upgrade to Pro+ | |
GSK plc | OTC Markets | Healthcare | Pharmaceuticals | $83.09B | 15.5x | -0.22 | $22 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
GSK plc DRC | NYSE | Healthcare | Pharmaceuticals | $83.09B | 15.5x | -0.22 | $40.98 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.3% Upside | Upgrade to Pro+ | |
Chugai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | $79.52B | 31.5x | 3.63 | $23.90 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Merck ADR | OTC Markets | Healthcare | Pharmaceuticals | $76.28B | 26x | -1.88 | $35.23 | -5.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.3% Upside | Upgrade to Pro+ | |
Daiichi Sankyo ADR | OTC Markets | Healthcare | Pharmaceuticals | $66.15B | 41.7x | 0.77 | $34.71 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.2% Upside | Upgrade to Pro+ | |
McKesson | NYSE | Healthcare | Pharmaceuticals | $65.71B | 22.6x | -1.35 | $506.68 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.5% Upside | Upgrade to Pro+ | |
Takeda Pharma ADR | NYSE | Healthcare | Pharmaceuticals | $47.68B | 44.9x | -0.86 | $14.79 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 17.8% Upside | Upgrade to Pro+ | |
Takeda Pharma | OTC Markets | Healthcare | Pharmaceuticals | $47.68B | 44.9x | -0.87 | $27.59 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HALEON ADR | NYSE | Healthcare | Pharmaceuticals | $47.36B | 33.2x | -2.89 | $10.54 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2% Upside | Upgrade to Pro+ | |
UCB ADR | OTC Markets | Healthcare | Pharmaceuticals | $34.26B | 128.9x | -4.66 | $90.83 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0.3% Upside | Upgrade to Pro+ | |
Bayer AG PK | OTC Markets | Healthcare | Pharmaceuticals | $31.33B | -22.2x | 0.11 | $7.99 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.8% Upside | Upgrade to Pro+ | |
Otsuka ADR | OTC Markets | Healthcare | Pharmaceuticals | $30.17B | 33.9x | -1.43 | $27.65 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.3% Upside | Upgrade to Pro+ |